← Back to All US Stocks

United Health Products, Inc. (UEEC) Stock Fundamental Analysis & AI Rating 2026

UEEC OTC Orthopedic, Prosthetic & Surgical Appliances & Supplies NV CIK: 0001096938
Recently Updated • Analysis: Apr 18, 2026 • SEC Data: 2025-12-31
STRONG SELL
98% Conf
Pending
Analysis scheduled

📊 UEEC Key Takeaways

Revenue: $0.0
Net Margin: N/A
Free Cash Flow: $-1.2M
Current Ratio: 0.03x
Debt/Equity: N/A
EPS: $-0.01
AI Rating: STRONG SELL with 98% confidence
United Health Products, Inc. (UEEC) receives a STRONG SELL rating with 98% confidence from our AI fundamental analysis based on SEC 10-K filings. With revenue of $0, United Health Products, Inc. demonstrates mixed fundamentals in the Healthcare sector. Below is our complete UEEC stock analysis for 2026.

Is United Health Products, Inc. (UEEC) a Good Investment?

Claude

United Health Products is in critical financial distress with zero revenue, negative stockholders' equity of -$3.9M, and a severe liquidity crisis (0.03x current ratio). The company is technically insolvent and burning cash at -$1.2M annually with no viable operational base, making bankruptcy an imminent risk without substantial capital restructuring.

Why Buy United Health Products, Inc. Stock? UEEC Key Strengths

Claude
  • + Company maintains SEC filing status indicating administrative continuity

UEEC Stock Risks: United Health Products, Inc. Investment Risks

Claude
  • ! Zero revenue indicates non-operational business with complete loss of customer base
  • ! Negative stockholders' equity means liabilities exceed assets - technical insolvency
  • ! Critical liquidity crisis: current ratio of 0.03x leaves company unable to service obligations
  • ! Operating cash flow of -$1.2M annually is unsustainable with only $65.2K cash remaining
  • ! Interest coverage of -19.9x shows company cannot service debt
  • ! High bankruptcy or liquidation risk without immediate capital infusion

Key Metrics to Watch

Claude
  • * Revenue generation and operational restart
  • * Cash burn rate and cash position depletion timeline
  • * Debt restructuring, capital raise, or bankruptcy announcements

United Health Products, Inc. (UEEC) Financial Metrics & Key Ratios

Revenue
$0.0
Net Income
$-2.7M
EPS (Diluted)
$-0.01
Free Cash Flow
$-1.2M
Total Assets
$316.7K
Cash Position
$65.2K

💡 AI Analyst Insight

The current ratio below 1.0x warrants monitoring of short-term liquidity.

UEEC Profit Margin, ROE & Profitability Analysis

Gross Margin N/A
Operating Margin N/A
Net Margin N/A
ROE N/A
ROA -842.9%
FCF Margin N/A

UEEC vs Healthcare Sector: How United Health Products, Inc. Compares

How United Health Products, Inc. compares to Healthcare sector averages

Net Margin
UEEC 0.0%
vs
Sector Avg 12.0%
UEEC Sector
ROE
UEEC 0.0%
vs
Sector Avg 15.0%
UEEC Sector
Current Ratio
UEEC 0.0x
vs
Sector Avg 2.0x
UEEC Sector
Debt/Equity
UEEC 0.0x
vs
Sector Avg 0.6x
UEEC Sector

Sector benchmarks are approximate industry averages. Actual sector performance may vary.

Is United Health Products, Inc. Stock Overvalued? UEEC Valuation Analysis 2026

Based on fundamental analysis, United Health Products, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.

Return on Equity
N/A
Sector avg: 15%
Net Profit Margin
N/A
Sector avg: 12%
Revenue Growth
N/A
Year-over-year
Debt/Equity
N/A
Sector avg: 0.6x

Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.

United Health Products, Inc. Balance Sheet: UEEC Debt, Cash & Liquidity

Current Ratio
0.03x
Quick Ratio
0.03x
Debt/Equity
N/A
Debt/Assets
1,324.0%
Interest Coverage
-19.91x
Long-term Debt
$927.5K

UEEC Revenue & Earnings Growth: 5-Year Financial Trend

UEEC 5-year financial data: Year 2021: Revenue $643, Net Income -$15.7M, EPS N/A. Year 2022: Revenue $37.5K, Net Income -$30.5M, EPS N/A. Year 2023: Revenue $37.5K, Net Income -$1.7M, EPS N/A. Year 2024: Revenue $0, Net Income -$2.6M, EPS $-0.01. Year 2025: Revenue $0, Net Income -$2.0M, EPS $-0.01.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: United Health Products, Inc.'s revenue has declined by 100% over the 5-year period, indicating business contraction. The most recent EPS of $-0.01 indicates the company is currently unprofitable.

UEEC Revenue Growth, EPS Growth & YoY Performance

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
N/A
Free cash flow / Revenue

UEEC Quarterly Earnings & Performance

Quarterly financial performance data for United Health Products, Inc. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 N/A -$285.6K $0.00
Q2 2025 N/A -$315.2K $0.00
Q1 2025 N/A -$451.9K $0.00
Q3 2024 N/A -$303.7K N/A
Q2 2024 N/A -$432.0K N/A
Q1 2024 N/A -$451.9K N/A
Q3 2023 N/A -$485.7K $0.00
Q2 2023 N/A -$522.9K N/A

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

United Health Products, Inc. Dividends, Buybacks & Capital Allocation

Operating Cash Flow
-$1.2M
Cash generated from operations
Dividends
None
No dividend program

UEEC SEC Filings: Latest 10-K & 10-Q Analysis

Access official SEC EDGAR filings for United Health Products, Inc. (CIK: 0001096938)

📋 Recent SEC Filings

Date Form Document Action
Apr 15, 2026 10-K ueec_10k.htm View →
Jan 15, 2026 S-1 ueec_s1.htm View →
Dec 22, 2025 8-K ueec_8k.htm View →
Nov 14, 2025 10-Q ueec_10q.htm View →
Aug 14, 2025 10-Q ueec_10q.htm View →

Frequently Asked Questions about UEEC

What is the AI rating for UEEC?

United Health Products, Inc. (UEEC) has an AI rating of STRONG SELL with 98% confidence, based on fundamental analysis of SEC EDGAR filings.

What are UEEC's key strengths?

Claude: Company maintains SEC filing status indicating administrative continuity.

What are the risks of investing in UEEC?

Claude: Zero revenue indicates non-operational business with complete loss of customer base. Negative stockholders' equity means liabilities exceed assets - technical insolvency.

What is UEEC's revenue and growth?

United Health Products, Inc. reported revenue of $0.0.

Does UEEC pay dividends?

United Health Products, Inc. does not currently pay dividends.

Where can I find UEEC SEC filings?

Official SEC filings for United Health Products, Inc. (CIK: 0001096938) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.

What is UEEC's EPS?

United Health Products, Inc. has a diluted EPS of $-0.01.

How is the AI analysis conducted?

Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.

Is UEEC a good stock to buy right now?

Based on our AI fundamental analysis in April 2026, United Health Products, Inc. has a STRONG SELL rating with 98% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.

Is UEEC stock overvalued or undervalued?

Valuation metrics for UEEC: ROE of N/A (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.

Should I buy UEEC stock in 2026?

Our dual AI analysis gives United Health Products, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.

What is UEEC's free cash flow?

United Health Products, Inc.'s operating cash flow is $-1.2M, with capital expenditures of $0.0.

How does UEEC compare to other Healthcare stocks?

Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE N/A (avg: 15%), current ratio 0.03 (avg: 2).

Top Rated Stocks
NSSC 92% MLI 92% MELI 92% MDXG 92% MANH 92% INVA 92% GGG 92% GCT 92% FTNT 92% FSLR 92%
Sector: All Healthcare Stocks →
Disclaimer: This analysis is generated by Claude AI (Anthropic) and ChatGPT (OpenAI) based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Apr 18, 2026 | Data as of: 2025-12-31 | Powered by Claude AI